{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:48:55Z","timestamp":1781300935278,"version":"3.54.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T00:00:00Z","timestamp":1664668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.xphs.2022.09.028","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T21:23:01Z","timestamp":1664832181000},"page":"599-609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Application of Virtual Therapeutic Drug Monitoring to Assess the Pharmacokinetics of Imatinib in a Chinese Cancer Population Group"],"prefix":"10.1016","volume":"112","author":[{"given":"He","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-9324","authenticated-orcid":false,"given":"Raj K. Singh","family":"Badhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.xphs.2022.09.028_bib0001","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","article-title":"Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy","volume":"12","author":"Pottier","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.xphs.2022.09.028_bib0002","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ejca.2021.08.033","article-title":"Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy","volume":"157","author":"Clarke","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.xphs.2022.09.028_bib0003","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fphar.2020.00177","article-title":"The steps to therapeutic drug monitoring: a structured approach illustrated with imatinib","volume":"11","author":"Buclin","year":"2020","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.xphs.2022.09.028_bib0004","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/bcp.13990","article-title":"Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: a cost-effectiveness study","volume":"85","author":"Zuidema","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2022.09.028_bib0005","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00280-014-2599-1","article-title":"Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial","volume":"74","author":"Gotta","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.xphs.2022.09.028_bib0006","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","article-title":"Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies","volume":"40","author":"S\u00f8reide","year":"2016","journal-title":"Cancer epidemiology"},{"issue":"1","key":"10.1016\/j.xphs.2022.09.028_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-14-102","article-title":"The epidemiology of gastrointestinal stromal tumors in Taiwan, 1998\u20132008: a nation-wide cancer registry-based study","volume":"14","author":"Chiang","year":"2014","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.xphs.2022.09.028_bib0008","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jjco\/hyt073","article-title":"Incidence of soft tissue sarcoma focusing on gastrointestinal stromal sarcoma in Osaka, Japan, during 1978\u20132007","volume":"43","author":"Nomura","year":"2013","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.xphs.2022.09.028_bib0009","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/cam4.3644","article-title":"Incidence of gastrointestinal stromal tumor in Chinese urban population: a national population-based study","volume":"10","author":"Xu","year":"2021","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.xphs.2022.09.028_bib0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1470-2045(11)70299-6","article-title":"Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts","volume":"13","author":"Joensuu","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.xphs.2022.09.028_bib0011","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3111\/13696998.2014.991787","article-title":"The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy","volume":"18","author":"Guerin","year":"2015","journal-title":"J Med Econ"},{"issue":"5","key":"10.1016\/j.xphs.2022.09.028_bib0012","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1634\/theoncologist.2015-0337","article-title":"Best practices in chronic myeloid leukemia monitoring and management","volume":"21","author":"Soverini","year":"2016","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.xphs.2022.09.028_bib0013","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.xphs.2022.09.028_bib0014","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.xphs.2022.09.028_bib0015","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance","author":"Bixby","year":"2009","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"7","key":"10.1016\/j.xphs.2022.09.028_bib0016","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.xphs.2022.09.028_bib0017","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2007.2002","article-title":"Management of patients with gastrointestinal stromal tumor (GIST)\u2013update of the NCCN clinical practice guidelines","volume":"5","author":"Demetri","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"10.1016\/j.xphs.2022.09.028_bib0018","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1124\/dmd.105.004283","article-title":"Metabolism and disposition of imatinib mesylate in healthy volunteers","volume":"33","author":"Gschwind","year":"2005","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.xphs.2022.09.028_bib0019","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/0091270003262101","article-title":"Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion","volume":"44","author":"Peng","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2022.09.028_bib0020","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.xphs.2022.09.028_bib0021","first-page":"3034","article-title":"Approval summary: imatinib mesylate in the treatment of metastatic and\/or unresectable malignant gastrointestinal stromal tumors","volume":"8","author":"Dagher","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xphs.2022.09.028_bib0022","first-page":"307a","author":"Reckmann","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.xphs.2022.09.028_bib0023","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.xphs.2022.09.028_bib0024","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nature medicine"},{"key":"10.1016\/j.xphs.2022.09.028_bib0025","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jchromb.2012.09.007","article-title":"Determination of unbound fraction of imatinib and N-desmethyl imatinib, validation of an UPLC-MS\/MS assay and ultrafiltration method","volume":"907","author":"Arellano","year":"2012","journal-title":"J Chromatogr B, Anal Technol Biomed Life Sci"},{"issue":"3","key":"10.1016\/j.xphs.2022.09.028_bib0026","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/00498254.2015.1060649","article-title":"Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib","volume":"46","author":"Khan","year":"2016","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.xphs.2022.09.028_bib0027","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/dmd.112.048017","article-title":"Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response","volume":"41","author":"Filppula","year":"2013","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.xphs.2022.09.028_bib0028","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/j.1476-5381.2010.00946.x","article-title":"Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes","volume":"161","author":"Nebot","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"8","key":"10.1016\/j.xphs.2022.09.028_bib0029","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates","volume":"165","author":"Filppula","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2022.09.028_bib0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/bdd.598","article-title":"In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1","volume":"29","author":"Rochat","year":"2008","journal-title":"Biopharm Drug Dispos"},{"issue":"8","key":"10.1016\/j.xphs.2022.09.028_bib0031","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40262-016-0494-0","article-title":"CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients","volume":"56","author":"Barratt","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.xphs.2022.09.028_bib0032","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.xphs.2022.09.028_bib0033","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF02353475","article-title":"Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans","volume":"24","author":"Wilkinson","year":"1996","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"10.1016\/j.xphs.2022.09.028_bib0034","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00007691-200404000-00019","article-title":"Genetics of the variable expression of CYP3A in humans","volume":"26","author":"Wojnowski","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.xphs.2022.09.028_bib0035","first-page":"141","article-title":"2013. A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer","volume":"34(3)","author":"Cheeti","year":"2013"},{"issue":"4","key":"10.1016\/j.xphs.2022.09.028_bib0036","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1054\/bjoc.2000.1643","article-title":"Estimation of glomerular filtration rate in cancer patients","volume":"84","author":"Wright","year":"2001","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.xphs.2022.09.028_bib0037","doi-asserted-by":"crossref","first-page":"281","DOI":"10.21147\/j.issn.1000-9604.2017.04.01","article-title":"Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor","volume":"29","author":"Li","year":"2017","journal-title":"Chin J Cancer Res"},{"issue":"12","key":"10.1016\/j.xphs.2022.09.028_bib0038","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ejca.2005.04.034","article-title":"Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg","volume":"41","author":"Zalcberg","year":"2005","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.xphs.2022.09.028_bib0039","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1200\/JCO.2007.13.4452","article-title":"Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"S9","key":"10.1016\/j.xphs.2022.09.028_bib0040","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/cncr.32684","article-title":"The current status of and prospects in research regarding gastrointestinal stromal tumors in China","volume":"126","author":"Li","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.xphs.2022.09.028_bib0041","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3748\/wjg.v18.i7.698","article-title":"Efficacy of imatinib dose escalation in Chinese gastrointestinal stromal tumor patients","volume":"18","author":"Li","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.xphs.2022.09.028_bib0042","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ctrv.2010.04.008","article-title":"Practical management of tyrosine kinase inhibitor-associated side effects in GIST","volume":"37","author":"Joensuu","year":"2011","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.xphs.2022.09.028_bib0043","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.xphs.2022.09.028_bib0044","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.xphs.2022.09.028_bib0045","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"issue":"32","key":"10.1016\/j.xphs.2022.09.028_bib0046","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2012.43.5362","article-title":"Evidence for therapeutic drug monitoring of targeted anticancer therapies","volume":"30","author":"Gao","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.xphs.2022.09.028_bib0047","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/FTD.0b013e318284ef11","article-title":"Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes","volume":"35","author":"Gotta","year":"2013","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.xphs.2022.09.028_bib0048","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.blre.2011.09.001","article-title":"Managing resistance in chronic myeloid leukemia","volume":"25","author":"Roychowdhury","year":"2011","journal-title":"Blood Rev"},{"issue":"8","key":"10.1016\/j.xphs.2022.09.028_bib0049","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/aps.2010.79","article-title":"Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients","volume":"31","author":"Li","year":"2010","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.xphs.2022.09.028_bib0050","first-page":"395","article-title":"Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients","volume":"7","author":"Zhu","year":"2014","journal-title":"Onco Targets Ther"},{"issue":"10","key":"10.1016\/j.xphs.2022.09.028_bib0051","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1016\/j.xphs.2021.05.008","article-title":"The pharmacokinetics of gefitinib in a chinese cancer population group: a virtual clinical trials population study","volume":"110","author":"Yu","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.09.028_bib0052","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/2193-9616-1-9","article-title":"The simcyp population based simulator: architecture, implementation, and quality assurance","volume":"1","author":"Jamei","year":"2013","journal-title":"In Silico Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2022.09.028_bib0053","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejps.2009.12.002","volume":"39","author":"Rowland Yeo","year":"2010","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.09.028_bib0054","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2133\/dmpk.24.53","volume":"24","author":"Jamei","year":"2009","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.xphs.2022.09.028_bib0055","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3389\/fphar.2019.01672","article-title":"Implementation of a physiologically based pharmacokinetic modeling approach to guide optimal dosing regimens for imatinib and potential drug interactions in paediatrics","volume":"10","author":"Adiwidjaja","year":"2019","journal-title":"Front Pharmacol"},{"issue":"21","key":"10.1016\/j.xphs.2022.09.028_bib0056","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","article-title":"Population pharmacokinetics and pharmacogenetics of imatinib in children and adults","volume":"14","author":"Petain","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.xphs.2022.09.028_bib0057","doi-asserted-by":"crossref","first-page":"5780","DOI":"10.1158\/1078-0432.CCR-12-0490","article-title":"A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients","volume":"18","author":"Eechoute","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.xphs.2022.09.028_bib0058","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/bcp.12584","article-title":"Pharmacokinetic interactions among imatinib, bosentan and sildenafil, and their clinical implications in severe pulmonary arterial hypertension","volume":"80","author":"Renard","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2022.09.028_bib0059","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/bdd.1830","article-title":"A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer","volume":"34","author":"Cheeti","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.xphs.2022.09.028_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2021.05.008","article-title":"The pharmacokinetics of gefitinib in a Chinese cancer population group: a virtual clinical trials population study","author":"Yu","year":"2021","journal-title":"J Pharm Sci"},{"issue":"S9","key":"10.1016\/j.xphs.2022.09.028_bib0061","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/cncr.32751","article-title":"Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors","volume":"126","author":"Xia","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.xphs.2022.09.028_bib0062","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1159\/000493195","article-title":"Relative factors analysis of imatinib trough concentration in chinese patients with gastrointestinal stromal tumor","volume":"63","author":"Wu","year":"2018","journal-title":"Chemotherapy"},{"issue":"4","key":"10.1016\/j.xphs.2022.09.028_bib0063","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000336244","article-title":"Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients","volume":"127","author":"Zhong","year":"2012","journal-title":"Acta Haematol"},{"issue":"12","key":"10.1016\/j.xphs.2022.09.028_bib0064","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1158\/1535-7163.MCT-18-0498","article-title":"Association of imatinib plasma concentration and single-nucleotide polymorphisms with adverse drug reactions in patients with gastrointestinal stromal tumors","volume":"17","author":"Zhang","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.xphs.2022.09.028_bib0065","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2020.05.025","article-title":"Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours \u2013 results from daily clinical practice","volume":"136","author":"Ijzerman","year":"2020","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.xphs.2022.09.028_bib0066","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1111\/bcp.13327","article-title":"Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib","volume":"83","author":"Lankheet","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2022.09.028_bib0067","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/FTD.0000000000000004","article-title":"Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care","volume":"36","author":"Lankheet","year":"2014","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.xphs.2022.09.028_bib0068","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40262-016-0439-7","article-title":"Imatinib pharmacokinetics in a large observational cohort of gastrointestinal stromal tumour patients","volume":"56","author":"Farag","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.xphs.2022.09.028_bib0069","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","article-title":"Development and evaluation of a generic physiologically based pharmacokinetic model for children","volume":"45","author":"Edginton","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.1016\/j.xphs.2022.09.028_bib0070","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2165\/11592640-000000000-00000","article-title":"Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants","volume":"50","author":"Parrott","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.xphs.2022.09.028_bib0071","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/15287390490273550","article-title":"Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents","volume":"67","author":"Ginsberg","year":"2004","journal-title":"J Toxicol Environ Health, Part A"},{"key":"10.1016\/j.xphs.2022.09.028_bib0072","series-title":"Summary Minutes of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology","author":"Food","year":"2012"},{"issue":"1","key":"10.1016\/j.xphs.2022.09.028_bib0073","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.xphs.2018.10.056","article-title":"Dose optimization of chloroquine by pharmacokinetic modeling during pregnancy for the treatment of Zika virus infection","volume":"108","author":"Olafuyi","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2022.09.028_bib0074","unstructured":"Almurjan A, Macfarlane H, Badhan RKS. The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study. Biopharmaceut Drug Disposition n\/a(n\/a)."},{"issue":"12","key":"10.1016\/j.xphs.2022.09.028_bib0075","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1002\/jps.21759","article-title":"Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods","volume":"98","author":"Poulin","year":"2009","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.xphs.2022.09.028_bib0076","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.xphs.2022.09.028_bib0077","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"issue":"10","key":"10.1016\/j.xphs.2022.09.028_bib0078","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.2165\/00003088-200645100-00005","article-title":"Development and evaluation of a generic physiologically based pharmacokinetic model for children","volume":"45","author":"Edginton","year":"2006","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.xphs.2022.09.028_bib0079","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.xphs.2022.09.028_bib0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00428-010-0891-y","article-title":"Gastrointestinal stromal tumors","volume":"456","author":"Liegl-Atzwanger","year":"2010","journal-title":"Virchows Arch"},{"issue":"4","key":"10.1016\/j.xphs.2022.09.028_bib0081","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijsu.2014.02.004","article-title":"Gastrointestinal stromal tumors (GIST) related emergencies","volume":"12","author":"Sorour","year":"2014","journal-title":"Int J Surg"},{"issue":"8","key":"10.1016\/j.xphs.2022.09.028_bib0082","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.xphs.2022.09.028_bib0083","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.xphs.2022.09.028_bib0084","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00280-003-0756-z","article-title":"Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules","volume":"53","author":"Nikolova","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.xphs.2022.09.028_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.569843","article-title":"Factors influencing the steady-state plasma concentration of imatinib mesylate in patients with gastrointestinal stromal tumors and chronic myeloid leukemia","volume":"11","author":"Chen","year":"2020","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.xphs.2022.09.028_bib0086","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'hare","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.xphs.2022.09.028_bib0087","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.leukres.2014.03.023","article-title":"Large-scale imatinib dose\u2013concentration\u2013effect study in CML patients under routine care conditions","volume":"38","author":"Gotta","year":"2014","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.xphs.2022.09.028_bib0088","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00277-008-0589-2","article-title":"Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients","volume":"88","author":"Kobayashi","year":"2009","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.xphs.2022.09.028_bib0089","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000111777","article-title":"Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area","volume":"118","author":"Park","year":"2007","journal-title":"Acta Haematol"},{"issue":"4","key":"10.1016\/j.xphs.2022.09.028_bib0090","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.leukres.2006.05.019","article-title":"Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML)","volume":"31","author":"Horikoshi","year":"2006","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.xphs.2022.09.028_bib0091","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0145-2126(03)00101-2","article-title":"Effects of lower dose of imatinib to CML patients","volume":"27","author":"Horikoshi","year":"2003","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.xphs.2022.09.028_bib0092","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF02982610","article-title":"Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?","volume":"77","author":"Miyazawa","year":"2003","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1016\/j.xphs.2022.09.028_bib0093","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2125.2008.03150.x","article-title":"Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia","volume":"65","author":"Wang","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2022.09.028_bib0094","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00228-009-0621-z","article-title":"Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders","volume":"65","author":"Singh","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2022.09.028_bib0095","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1111\/ijd.13111","article-title":"Clinical and histopathologic analysis of 46 cases of cutaneous adverse reactions to imatinib","volume":"55","author":"Lee","year":"2016","journal-title":"Int J Dermatol"},{"issue":"7","key":"10.1016\/j.xphs.2022.09.028_bib0096","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ad.2013.01.009","article-title":"Adverse skin effects of imatinib, a tyrosine kinase inhibitor","volume":"105","author":"Pretel-Irazabal","year":"2014","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"10.1016\/j.xphs.2022.09.028_bib0097","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/jcpt.13201","article-title":"Therapeutic drug monitoring-based dose optimization for imatinib-associated serious cutaneous reactions in a patient with gastrointestinal stromal tumours: a case report","volume":"45","author":"Huang","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.xphs.2022.09.028_bib0098","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3346\/jkms.2013.28.8.1248","article-title":"Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients","volume":"28","author":"Yoon","year":"2013","journal-title":"J Korean Med Sci"},{"issue":"8","key":"10.1016\/j.xphs.2022.09.028_bib0099","first-page":"1077","article-title":"The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia","volume":"27","author":"Conti","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2022.09.028_bib0100","doi-asserted-by":"crossref","first-page":"FSO92","DOI":"10.4155\/fso.15.92","article-title":"Clinical development of imatinib: an anticancer drug","volume":"2","author":"Goswami","year":"2016","journal-title":"Future Sci OA"},{"issue":"5","key":"10.1016\/j.xphs.2022.09.028_bib0101","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s13318-015-0292-3","article-title":"Population pharmacokinetic analysis of the oral absorption process and explaining intra-subject variability in plasma exposures of imatinib in healthy volunteers","volume":"41","author":"Golabchifar","year":"2016","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.xphs.2022.09.028_bib0102","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF03256440","article-title":"Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals","volume":"10","author":"Garcia-Martin","year":"2006","journal-title":"Mol Diagn Ther"},{"issue":"10","key":"10.1016\/j.xphs.2022.09.028_bib0103","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1177\/0091270004268128","article-title":"Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms","volume":"44","author":"Kim","year":"2004","journal-title":"J Clin Pharmacol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922004506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354922004506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:39:56Z","timestamp":1758361196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354922004506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":103,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0022354922004506"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2022.09.028","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Application of Virtual Therapeutic Drug Monitoring to Assess the Pharmacokinetics of Imatinib in a Chinese Cancer Population Group","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2022.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}